11 Sep 2018 09:58
11 September 2018
SINCLAIR PHARMA PLC
RE UPDATE RE POSSIBLE OFFER FOR SINCLAIR PHARMA PLC
London, 11 September 2018 Sinclair Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international aesthetics company, notes the announcement made today via RNS by Huadong Medicine Co., Limited ("HMC") stating that the ODI Pre-Condition has now been satisfied. The Guarantee Pre-Condition and the Recommendation Pre-Condition remain to be satisfied. A copy of the announcement is available on the Group's website.
For further information please contact:
Sinclair Pharma plc | Tel: +44 (0) 20 7467 6920 |
Grahame Cook Chris Spooner Alan Olby Andy Crane |
|
Rothschild (Lead Financial Adviser to Sinclair) | Tel: +44 (0)20 7280 5000 |
Dominic Hollamby Julian Hudson |
|
Peel Hunt (Joint Financial Adviser, Nominated Adviser and Joint Broker to Sinclair) James Steel Michael Nicholson Oliver Jackson | Tel: +44 (0)20 7418 8900 |
Notes to Editors:
About Sinclair Pharma plc - www.sinclairpharma.com
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. Sinclair is planning entry to multiple new geographic markets and line extension launches over the next few years. The Group has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. The Group has recently established a direct presence in the US.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward‐looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward‐looking statements due to a variety of factors.
N M Rothschild & Sons Limited ("Rothschild"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Sinclair and for no-one else in connection with the matters referred to in this announcement and will not be responsible to any person other than Sinclair for providing the protections afforded to clients of Rothschild, nor for providing advice in relation to the matters referred to herein. Neither Rothschild nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Rothschild in connection with the matters referred to in this announcement, or otherwise.
Peel Hunt LLP ("Peel Hunt"), which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Sinclair and for no-one else in connection with the matters referred to in this announcement and will not be responsible to any person other than Sinclair for providing the protections afforded to clients of Peel Hunt, nor for providing advice in relation to the matters referred to herein. Neither Peel Hunt nor any of its affiliates owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Peel Hunt in connection with the matters referred to in this announcement, or otherwise.